Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 1/2 3Phase 3 1

Status

Recruiting 3Withdrawn 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 3

Interventions

pembrolizumab 109Cyclophosphamide 89fludarabine 70Carboplatin 57Injections 56Bevacizumab 49Specimen Handling 43Gemcitabine 41Magnetic Resonance Spectroscopy 40Paclitaxel 39Nivolumab 38venetoclax 36Dexamethasone 35Cisplatin 34Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Capecitabine 27Oxaliplatin 26Fluorouracil 26Pemetrexed 24Irinotecan 24Azacitidine 24abemaciclib 23toripalimab 22Fulvestrant 22fludarabine phosphate 21Rituximab 21Leucovorin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × CPX-351 × Clear all
NCT04049539 2026-04-08

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
28 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04990102 2026-03-23

Phase IB/II of CPX-351 for Relapse Prevention in AML

Georgetown University

Phase 1/2 Recruiting
24 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07008638 2025-07-09

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Masonic Cancer Center, University of Minnesota

Phase 1/2 Recruiting
32 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡